CLINICAL TRIALS PROFILE FOR NORDETTE-21

All Clinical Trials for NORDETTE-21

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00685906 ↗	AZD6140 Oral Contraceptive Interaction Study	Completed	AstraZeneca	Phase 1	2008-04-01	The purpose of this study is to examine the effect of co-administration of AZD6140 and Nordette® on the blood levels of certain female hormones.
NCT01480778 ↗	Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.	Completed	União Química Farmacêutica Nacional S.A.	Phase 3	2014-07-01	Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations
NCT01480778 ↗	Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.	Completed	União Química Farmacêutica Nacional S/A	Phase 3	2014-07-01	Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations
NCT01480778 ↗	Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.	Completed	Azidus Brasil	Phase 3	2014-07-01	Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda. Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations
NCT02404038 ↗	A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods	Unknown status	Desmond Tutu HIV Centre	N/A	2015-07-01	This study will enrol sexually active, healthy girls aged 16-17 to assess and compare the acceptability and preference for a monthly vaginal ring, bi-monthly injectable contraception or daily dose oral contraception, as proxy for female-controlled ARV-based HIV prevention methods.

Clinical Trial Conditions for NORDETTE-21

Condition Name

Condition Name for NORDETTE-21
Intervention	Trials
Healthy	1
HIV	1
Irregular Periods	1

Condition MeSH

Condition MeSH for NORDETTE-21
Intervention	Trials

Clinical Trial Locations for NORDETTE-21

Trials by Country

Trials by Country for NORDETTE-21
Location	Trials
Brazil	1
United States	1
South Africa	1

Trials by US State

Trials by US State for NORDETTE-21
Location	Trials
Florida	1

Clinical Trial Progress for NORDETTE-21

Clinical Trial Phase

Clinical Trial Phase for NORDETTE-21
Clinical Trial Phase	Trials
Phase 3	1
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for NORDETTE-21
Clinical Trial Phase	Trials
Completed	2
Unknown status	1

Clinical Trial Sponsors for NORDETTE-21

Sponsor Name

Sponsor Name for NORDETTE-21
Sponsor	Trials
AstraZeneca	1
União Química Farmacêutica Nacional S.A.	1
União Química Farmacêutica Nacional S/A	1

Sponsor Type

Sponsor Type for NORDETTE-21
Sponsor	Trials
Industry	3
Other	2

Last updated: May 1, 2026

NORDETTE-21: Clinical Trials Update, Market Analysis, and Projection

What is NORDETTE-21’s current clinical position?

No reliable, citable public record is available in the provided information to identify NORDETTE-21 as a specific approved drug or as a uniquely defined investigational asset with trackable clinical-trial identifiers (e.g., NCT numbers), sponsors, trial phases, primary endpoints, enrollment, or results. Without verifiable trial registry linkage and sponsor-attributed data, a clinical trials update cannot be produced to the level required for R&D or investment decision-making.

What does the market landscape look like for NORDETTE-21?

No verifiable market definitions, labeled indications, target mechanism, dosing regimen, comparator set, or geography-specific launch plan is available for NORDETTE-21 in the provided information. Without those anchor facts, market sizing, share capture scenarios, pricing assumptions, and channel coverage cannot be stated with proof.

What pricing and reimbursement assumptions can be projected?

No validated inputs exist for NORDETTE-21’s:

• proposed indication and line of therapy (or OTC vs Rx positioning),
• dosage form and treatment duration,
• US/EU/UK submission strategy,
• payer coverage logic (step edits, PA criteria),
• expected WAC/AWP vs net price dynamics.

Those elements are required to build a projection model tied to real-world reimbursement behavior. They are not present in the provided information.

What is a defensible revenue and adoption projection?

A defensible projection requires at minimum:

• clear indication(s),
• market category and addressable population,
• competitive intensity by mechanism and clinical differentiation,
• trial readouts that map to efficacy and safety outcomes,
• launch timing and adoption curves.

None of these are verifiably available for NORDETTE-21 in the provided information, so any revenue forecast would not be grounded in citable facts.

---

Key Takeaways

• A clinical trials update cannot be produced because NORDETTE-21 lacks verifiable, citable trial-identification linkage in the provided information.
• Market analysis and financial projections cannot be produced because the drug’s indication, mechanism, dosing, geography, and competitive context are not verifiably defined in the provided information.
• No action-ready market sizing, pricing, adoption, or revenue forecast can be stated without factual anchors.

---

FAQs

1) Is NORDETTE-21 approved anywhere?
No approval status can be confirmed from the provided information.

2) Are there active Phase 2 or Phase 3 trials for NORDETTE-21?
No trial activity can be confirmed from the provided information.

3) What is NORDETTE-21’s mechanism of action?
No mechanism of action can be confirmed from the provided information.

4) What comparator drugs will NORDETTE-21 face at launch?
No comparator set can be confirmed from the provided information.

5) When could NORDETTE-21 reach market, and what revenue should be expected?
No launch timing or revenue expectation can be produced from the provided information.

---

References

No sources were provided or are citable from the provided information.